| Bioactivity | WNY1613 is a potent and selective PI3Kδ inhibitor with piperazinone-containing purine scaffold. WNY1613 induces cancer cell apoptosis and inhibits the phosphorylation of PI3K downstream components in NHL cell lines. WNY1613 exhibits anti-NHL activity in vitro and in vivo[1]. |
| Name | WNY1613 |
| CAS | 2650546-39-5 |
| Formula | C29H35N9O3 |
| Molar Mass | 557.65 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
WNY1613
CAS: 2650546-39-5 F: C29H35N9O3 W: 557.65
WNY1613 is a potent and selective PI3Kδ inhibitor with piperazinone-containing purine scaffold. WNY1613 induces cancer
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.